Efficacy and Safety of Salvage Surgery After Immunotherapy in Non-small Cell Lung Cancer: A Multi-institutional Retrospective Study - PubMed
5 hours ago
- #Salvage surgery
- #Non-small cell lung cancer
- #Immunotherapy
- Study evaluates salvage surgery after immunotherapy in non-small cell lung cancer (NSCLC).
- Multi-institutional retrospective analysis of 32 patients from 14 centers in Japan (2016-2023).
- Salvage surgery classified as conversion surgery (downstaging) or true salvage surgery (local recurrence/residual disease).
- Perioperative outcomes, overall survival (OS), and recurrence-free survival (RFS) were primary endpoints.
- Radiologic response to ICI: 12.5% complete, 71.9% partial, 15.6% stable disease.
- True salvage surgery (53.1%) vs. conversion surgery (46.9%). Lobectomy performed in 84.4% of cases.
- 25% perioperative complications, no mortality. 18.8% achieved pathologic complete response.
- 3- and 5-year OS rates: 86.9% and 77.2%, respectively.
- Conversion surgery showed superior 3-year RFS (92.8%) vs. true salvage (36.3%).
- Salvage surgery is safe with encouraging survival, especially for conversion surgery cases.